首页> 中文期刊>中国医药 >钙调节蛋白在七氟烷后处理心脏保护中的机制探讨

钙调节蛋白在七氟烷后处理心脏保护中的机制探讨

摘要

Objective To discuss the mechanism of calcium regulatory proteins in cardiac protection after sevoflurane postconditioning (SevoPoC).Methods Isolated hearts were separated from 30 SD rats to make ischemia-reperfusion injury(I/RI) models and they were randomly divided into 3 groups(n =10):①Time control (TC) group had continuous perfusion of oxygenated KH solution for 120 min;②I/RI group had continuous perfusion of oxygenated KH solution for 30 min,stopped 30 min,and then reperfused for 60 min;③SevoPoC group had continuous perfusion of oxygenated KH solution for 30 min,stopped 30 min,and then had 3% sevoflurane perfusion for 10 min and KH solution perfusion for 50 min.Left ventricular end-diastolic pressure(LVEDP),heart rate(HR),left ventricular developed pressure(LVDP),the maximum LVDP increase rate(+ dp/dt) and the maximum LVDP decrease rate were observed.Myocardial infarct size was measured.Cardiac troponin (cTnI) in coronary outflow fluid was tested.Expressions of L-type Ca2+ channels (LTCCs),ryanodine receptor 2 (RyR2) and Na +-Ca2+ exchanger isoform 1 (NCX1) were determined.Results LVEDP in SevoPoC group was significantly lower,RPP(HR × LVDP) and + dp/dt were significantly higher than those in I/RI group (P < 0.05).Level of cTnI in SevoPoC group was significantly lower than that in I/RI group[(0.060 ±0.003)mg/L vs (0.110 ±0.004)mg/L](P <0.01).NCX1 expression level in I/RI group was significantly higher than that in TC group[(0.59 ±0.09) vs (0.35 ± 0.05)];NCX1 expression level in SevoPoC group (0.32 ± 0.06) was significantly lower than that in I/RI group(P < 0.01).Expressions of LTCCs and RyR2 showed no significant differences among groups(P > 0.05).Conclusion SevoPoC can promote cardiac function recovery,increase cTnI release in coronary outflow fluid and reduce infarction size;the cardioprotection effect may be associated with NCX1 deactivation.%目的 探讨钙调节蛋白在七氟烷后处理(SevoPoC)心脏保护中的机制.方法 选取30只SD大鼠建立离体心脏模型,血流动力学稳定30 min后,缺血30 min复灌60 min建立缺血再灌注损伤模型,完全随机分入以下3组,每组10只:①时间对照组(TC组):将离体心脏在恒流下灌注充分氧合的KH液120 min;②缺血再灌注组(I/RI组):将离体心脏在恒流下灌注充分氧合的KH液30 min后,停止灌注30 min,随后恢复灌注60 min;③七氟烷后处理组(SevoPoC组):将离体心脏在恒流下灌注充分氧合的KH液30 min后,停止灌注30 min,在复灌即刻使用含3%的七氟烷持续灌注10 min,然后使用氧合的KH液灌注50 min.各实验组均持续监测左心室舒张末期压力(LVEDP)、心率、左心室发展压(LVDP)、最大LVDP上升速率(+ dp/dt)及最大LVDP下降速率.检测心肌梗死面积和冠状动脉流出液中心肌肌钙蛋白I(cTnI)水平.分别用蛋白印迹法和荧光实时定量聚合酶链反应(RT-PCR)方法检测L型钙通道(LTCCs)、兰尼碱受体2(RyR2)以及钠钙交换体1(NCX1)的蛋白和基因转录水平.结果 SevoPoC能明显加快LVEDP、RPP(心率与LVDP的乘积)和+dp/dt向基线水平恢复,SevoPoC组LVEDP水平低于,RPP及+dp/dt高于I/RI组(均P<0.05).同时,SevoPoC可以降低心肌缺血再灌注损伤后cTnI的释放,SevoPoC组cTnI水平低于I/RI组[(0.060 ±0.003) mg/L比(0.110±0.004) mg/L](P<0.01).NCX1相对表达水平I/RI组高于TC组[(0.59±0.09)比(0.35±0.05)],SevoPoC组(0.32 ±0.06)低于I/RI组(均P<0.01).LTCCs和RyR2的表达各组间差异无统计学意义(P>0.05).结论 SevoPoC可以提供心肌保护作用,表现在心功能恢复的增强、冠状动脉流出液cTnI释放以及心肌梗死面积的减少.其作用可能与其对NCX1的抑制有关.

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号